3 results match your criteria: "University Hospitals of Leuven and KU Leuven[Affiliation]"
Practice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network.
Bone Marrow Transplant
September 2022
Department of Internal Medicine III, Faculty of Medicine, University Hospital Regensburg, Regensburg, Germany.
Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS).
Bone Marrow Transplant
January 2022
Section of Hematology, Centre Hospitalier Universitaire de Liège, Université de Liège, Liège, Belgium.
[C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson's disease and healthy volunteers.
Eur J Nucl Med Mol Imaging
September 2019
Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Leuven and KU Leuven, Leuven, Belgium.
Purpose: The P2X7 receptor (P2X7R) is an ATP-gated ion channel predominantly expressed on activated microglia and is important in neurodegenerative diseases including Parkinson's disease (PD). In this first-in-human study, we investigated [C]JNJ54173717 ([C]JNJ717), a selective P2X7R tracer, in healthy volunteers (HV) and PD patients. Biodistribution, dosimetry, kinetic modelling and short-term test-retest variation (TRV), as well as possible genotype effects, were investigated.
View Article and Find Full Text PDF